文献速递精神分裂症与精神病性障碍心境障碍焦虑、强迫与应激相关障碍

精神病临床高危人群共病精神障碍的Meta分析患病率:跨诊断评估的必要性

Meta-analytic prevalence of comorbid mental disorders in individuals at clinical high risk of psychosis: the case for transdiagnostic assessment.
PubMed 文献 · Mol Psychiatry · 2023-06-09

该系统Meta分析纳入312项研究,最大合并样本7834例,评估精神病临床高危(CHR-P)人群共病精神障碍的患病率及其影响。结果显示任何共病非精神病性精神障碍患病率为0.78,共病心境障碍为0.44,焦虑障碍为0.34,且共病状态与基线功能及精神病转化相关,提示应进行跨诊断评估。

要点

  • CHR-P个体中任何共病非精神病性精神障碍的合并患病率高达0.78。
  • 共病心境障碍和焦虑障碍的患病率分别为0.44和0.34。
  • 共病心境障碍/广泛性焦虑障碍/广场恐惧症与较低的精神病转化风险相关。

核心结论

  • 超过四分之三的CHR-P个体存在共病精神障碍,共病影响基线功能与精神病转化,应进行跨诊断评估。

研究设计与样本

  • 遵循PRISMA/MOOSE的系统Meta分析,检索PubMed/PsycInfo至2021年6月21日,纳入312项观察性研究/随机对照试验,最大合并样本7834例。

主要发现

  • 任何共病非精神病性精神障碍患病率为0.78(95%CI 0.73-0.82,k=29)。
  • 任何心境障碍患病率为0.44(95%CI 0.39-0.49,k=48),任何抑郁障碍/发作患病率为0.38(95%CI 0.33-0.42,k=50)。
  • 任何焦虑障碍患病率为0.34(95%CI 0.30-0.38,k=69),重性抑郁障碍患病率为0.30(95%CI 0.25-0.35,k=35)。
  • 任何共病精神障碍患病率随时间下降(96个月时为0.51,95%CI 0.25-0.77),但任何物质使用障碍随时间增加(>96个月时为0.19,95%CI 0.00-0.39,k=2)。
  • 与无精神病对照组相比,CHR-P状态与更高的焦虑、分裂型人格、惊恐和酒精使用障碍患病率相关(OR 2.90至1.54)。

关键数值与推荐

  • 任何共病非精神病性精神障碍患病率0.78(95%CI 0.73-0.82)。
  • 任何心境障碍患病率0.44(95%CI 0.39-0.49),任何焦虑障碍患病率0.34(95%CI 0.30-0.38)。
  • 与无精神病对照组相比,CHR-P状态与焦虑/心境障碍患病率较高相关(OR 9.30至2.02)。

临床怎么用

  • 对CHR-P个体应进行跨诊断精神健康评估,以识别共病并指导干预。

局限性

  • 研究间异质性高(71.01%的估计I2>50%),部分结局纳入研究数量少(如焦虑/心境障碍k=3)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Comorbid mental disorders in subjects at clinical high risk for psychosis (CHR-P) may impact preventive care. We conducted a PRISMA/MOOSE-compliant systematic meta-analysis, searching PubMed/PsycInfo up to June 21st, 2021 for observational studies/randomized controlled trials reporting on comorbid DSM/ICD-mental disorders in CHR-P subjects ( protocol ). The primary and secondary outcomes were baseline and follow-up prevalence of comorbid mental disorders. We also explored the association of comorbid mental disorders compared with CHR-P versus psychotic/non-psychotic control groups, their impact on baseline functioning and transition to psychosis. We conducted random-effects meta-analyses, meta-regression, and assessed heterogeneity/publication bias/quality (Newcastle Ottawa Scale, NOS). We included 312 studies (largest meta-analyzed sample = 7834, any anxiety disorder, mean age = 19.98 (3.40), females = 43.88%, overall NOS > 6 in 77.6% of studies). The prevalence was 0.78 (95% CI = 0.73-0.82, k = 29) for any comorbid non-psychotic mental disorder, 0.60 (95% CI = 0.36-0.84, k = 3) for anxiety/mood disorders, 0.44 (95% CI = 0.39-0.49, k = 48) for any mood disorders, 0.38 (95% CI = 0.33-0.42, k = 50) for any depressive disorder/episode, 0.34 (95% CI = 0.30-0.38, k = 69) for any anxiety disorder, 0.30 (95% CI 0.25-0.35, k = 35) for major depressive disorders, 0.29 (95% CI, 0.08-0.51, k = 3) for any trauma-related disorder, 0.23 (95% CI = 0.17-0.28, k = 24) for any personality disorder, and <0.23 in other mental disorders (I2 > 50% in 71.01% estimates). The prevalence of any comorbid mental disorder decreased over time (0.51, 95% CI = 0.25-0.77 over 96 months), except any substance use which increased (0.19, 95% CI = 0.00-0.39, k = 2, >96 months). Compared with controls, the CHR-P status was associated with a higher prevalence of anxiety, schizotypal personality, panic, and alcohol use disorders (OR from 2.90 to 1.54 versus without psychosis), a higher prevalence of anxiety/mood disorders (OR = 9.30 to 2.02) and lower prevalence of any substance use disorder (OR = 0.41, versus psychosis). Higher baseline prevalence of alcohol use disorder/schizotypal personality disorder was negatively associated with baseline functioning (beta from -0.40 to -0.15), while dysthymic disorder/generalized anxiety disorder with higher functioning (beta 0.59 to 1.49). Higher baseline prevalence of any mood disorder/generalized anxiety disorder/agoraphobia (beta from -2.39 to -0.27) was negatively associated with transition to psychosis. In conclusion, over three-quarters of CHR-P subjects have comorbid mental disorders, which modulate baseline functionig and transition to psychosis. Transdiagnostic mental health assessment should be warranted in subjects at CHR-P.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Solmi M, Soardo L, Kaur S, et al. Meta-analytic prevalence of comorbid mental disorders in individuals at clinical high risk of psychosis: the case for transdiagnostic assessment. Mol Psychiatry. 2023. PMID: 37296309. doi:10.1038/s41380-023-02029-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。